Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sherri Albertson

Nurse Practitioner, Psychiatric/Mental Health Fort Wayne, IN Nurse Practitioner

NPI 1609437425 CMS profile 10933826

2710 Lake Ave, Fort Wayne, IN 46805

Open in the dashboard

General payments

$6,182

358 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sherri Albertson of Fort Wayne, IN is reported in the CMS Open Payments database as having received $6,182 across 358 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,035 55
2024 General $1,019 59
2023 General $1,487 90
2022 General $1,214 76
2021 General $1,427 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sherri Albertson
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Sherri Albertson were reported at $1,035. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Sherri Albertson Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,427 $166 $54–$482 $132
2022 $1,214 $195 $66–$559 $149
2023 $1,487 $233 $82–$673 $160
2024 $1,019 $236 $84–$688 $164
2025 $1,035 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $839 72 payments
  2. Sunovion Pharmaceuticals Inc. $780 40 payments
  3. Supernus Pharmaceuticals, Inc. $595 48 payments
  4. Neurocrine Biosciences, Inc. $506 17 payments
  5. Otsuka America Pharmaceutical, Inc. $488 22 payments
  6. Axsome Therapeutics, Inc. $363 10 payments
  7. Lundbeck LLC $357 29 payments
  8. Alkermes, Inc. $328 18 payments
  9. Vanda Pharmaceuticals Inc. $323 24 payments
  10. Teva Pharmaceuticals USA, Inc. $320 13 payments
  11. Other $1,283 65 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,050 346 payments
  2. Education $132 12 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $839 72 payments
  2. LATUDA $780 40 payments
  3. Auvelity $363 10 payments
  4. ARISTADA Cns $328 18 payments
  5. ARISTADA Cns $328 18 payments
  6. Qelbree $328 26 payments
  7. FANAPT $323 24 payments
  8. INGREZZA $312 12 payments
  9. REXULTI $306 13 payments
  10. LYBALVI $287 16 payments
  11. Other $3,345 182 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

852

Median for Nurse Practitioner: 389

Drug cost

$319,741

Median for Nurse Practitioner: $21,885

Branded share of claims

17.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 21 $177,791
Vraylar Cariprazine Hcl Brand 32 $45,088
Rexulti Brexpiprazole Brand 21 $41,915
Lybalvi Olanzapine/Samidorphan Malate Brand 15 $22,975
Trintellix Vortioxetine Hydrobromide Brand 15 $11,153
Atomoxetine Hcl Generic 12 $2,568
Aripiprazole Generic 36 $2,295
Lurasidone Hcl Generic 18 $2,113
Duloxetine Hcl Generic 66 $2,042
Trazodone Hcl Generic 83 $1,513

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $157
  • Lundbeck LLC $54
$211 21 —
Qelbree
  • Supernus Pharmaceuticals, Inc. $202
$202 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $196
$196 — —
VRAYLAR
  • AbbVie, Inc. $160
$160 32 —
ARISTADA
  • Alkermes, Inc. $41
$41 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

358 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record